title: Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes.
abstract: Venous thromboembolism and adverse pregnancy outcomes are potential complications of pregnancy. Numerous studies have evaluated both the risk factors for and the prevention and management of these outcomes in pregnant patients. This consensus group was convened to provide concise recommendations, based on the currently available literature, regarding the use of antithrombotic therapy in pregnant patients at risk for venous thromboembolic events and adverse pregnancy outcomes.
authors.affiliation: Department of Obstetrics and Gynecology, Mercy Hospital of Pittsburgh, Pittsburgh, PA, USA.
authors.forename: Adam J
authors.initials: AJ
authors.lastname: Duhl
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Paidas
authors.forename: Serdar H
authors.initials: SH
authors.lastname: Ural
authors.forename: Ware
authors.initials: W
authors.lastname: Branch
authors.forename: Holly
authors.initials: H
authors.lastname: Casele
authors.forename: Joan
authors.initials: J
authors.lastname: Cox-Gill
authors.forename: Sheri Lynn
authors.initials: SL
authors.lastname: Hamersley
authors.forename: Thomas M
authors.initials: TM
authors.lastname: Hyers
authors.forename: Vern
authors.initials: V
authors.lastname: Katz
authors.forename: Randall
authors.initials: R
authors.lastname: Kuhlmann
authors.forename: Edith A
authors.initials: EA
authors.lastname: Nutescu
authors.forename: James A
authors.initials: JA
authors.lastname: Thorp
authors.forename: James L
authors.initials: JL
authors.lastname: Zehnder
mesh_terms: D000328:Adult; D000765:Anesthesia, Conduction; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000990:Antithrombin III / Q000032:analysis / Q000627:therapeutic use; D000991:Antithrombins / Q000032:analysis; D002585:Cesarean Section; D036861:Delivery, Obstetric; D005260:Female; D005333:Fetus / Q000187:drug effects; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage; D006801:Humans; D009765:Obesity / Q000453:epidemiology / Q000503:physiopathology; D016017:Odds Ratio; D049590:Postpartum Period; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000453:epidemiology / Q000503:physiopathology / Q000517:prevention & control / Q000628:therapy*; D011256:Pregnancy Outcome; D018570:Risk Assessment; D012307:Risk Factors; D013921:Thrombocytopenia / Q000139:chemically induced / Q000628:therapy; D015912:Thrombolytic Therapy; D019851:Thrombophilia; D054556:Venous Thromboembolism / Q000453:epidemiology / Q000503:physiopathology / Q000517:prevention & control / Q000628:therapy*; D014859:Warfarin / Q000009:adverse effects
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D006495:Heparin, Low-Molecular-Weight; D014859:Warfarin; D000990:Antithrombin III; D006493:Heparin